Immune Checkpoint Therapy for Thymic Carcinoma

TL;DR

This paper reviews how immune checkpoint therapy may help treat thymic carcinoma, a rare cancer, and discusses its effectiveness, safety, and future directions.

Contribution

The paper provides a comprehensive review of immune checkpoint inhibitors in thymic carcinoma, highlighting biomarkers and combination therapies.

Findings

PD-1/PD-L1 inhibitors show disease control in some TC patients, especially those with PD-L1 positivity.

Combination therapies with anti-angiogenic agents or chemotherapy may improve outcomes in subsets of TC patients.

Immune-related adverse events are less frequent in TC compared to thymoma but still require monitoring.

Abstract

Thymic carcinoma (TC) is rare and aggressive. For unresectable or advanced disease, platinum-based chemotherapy remains first-line, but a durable benefit is uncommon. PD-1/PD-L1 inhibitors provide an option after platinum in selected patients: objective responses occur in a minority, disease control in more, and signals are stronger in PD-L1–positive tumors despite low tumor mutational burden. Toxicities appear less frequent than in thymoma, yet hepatitis, myositis, and myocarditis require vigilant monitoring. Beyond monotherapy, combinations with anti-angiogenic agents or chemotherapy are being tested and may extend control in subsets. This review synthesizes efficacy, safety, and biomarkers of immune checkpoint blockade in TC, and offers practical points on perioperative use, patient selection, and surveillance.

Thymic carcinoma (TC) is a rare, aggressive cancer that originates from thymus’s epithelial cells. It distinguishes itself from other thymic epithelial tumors with its unique pathological structure, clinical behavior, and immune characteristics. Immune checkpoint inhibitors (ICIs) targeting the Programmed cell death protein 1/Programmed cell death protein ligand 1 (PD-1/PD-L1) pathway have shown promise in advanced TC, potentially benefiting from frequent PD-L1 overexpression and abundant CD8+ tumor-infiltrating lymphocytes (TILs), despite typically low tumor mutational burden (TMB). While ICI monotherapy can achieve disease control in some patients, its overall efficacy is limited and it is associated with a distinct profile of immune-related adverse events (irAEs) which occur less often than in thymomas. The predictive value of biomarkers—particularly PD-L1 expression—remains uncertain, underscoring the importance of consistent assessment criteria. In this review, we summarize evidence on ICI monotherapy as well as combination approaches that incorporate anti-angiogenic agents, chemotherapy, or dual checkpoint blockade. Emerging therapeutic targets—such as CD70, TIM-3, and B7-H4—are also considered in the context of their potential clinical relevance. Finally, we discuss future directions aimed at improving efficacy, extending response durability, and reducing treatment-related toxicity through biomarker-based patient selection and tailored therapeutic strategies.

Figures